Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey.

Lammers A, Mitin T, Moghanaki D, Thomas CR Jr, Timmerman R, Golden SE, Thakurta S, Dziadziuszko R, Slatore CG.

Adv Radiat Oncol. 2018 Jan 31;3(2):125-129. doi: 10.1016/j.adro.2018.01.001. eCollection 2018 Apr-Jun.

2.

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J.

Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121.

3.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10.

PMID:
29636358
4.

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.

Szymański FM, Płatek AE, Dziadziuszko R, Łęgosz P, Palczewski P.

Kardiol Pol. 2018;76(3):670. doi: 10.5603/KP.2018.0061. No abstract available.

5.

NSCLC molecular testing in Central and Eastern European countries.

Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J.

BMC Cancer. 2018 Mar 9;18(1):269. doi: 10.1186/s12885-018-4023-4.

6.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

7.

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium.

J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27.

PMID:
29191776
8.

MHC class II expression in lung cancer.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Lung Cancer. 2017 Oct;112:75-80. doi: 10.1016/j.lungcan.2017.07.030. Epub 2017 Jul 29.

PMID:
29191604
9.

Serum lipid profile discriminates patients with early lung cancer from healthy controls.

Ros-Mazurczyk M, Jelonek K, Marczyk M, Binczyk F, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Lung Cancer. 2017 Oct;112:69-74. doi: 10.1016/j.lungcan.2017.07.036. Epub 2017 Aug 1.

PMID:
29191603
10.

Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors.

Skrzypski M, Szymanowska-Narloch A, Dziadziuszko R.

Contemp Oncol (Pozn). 2017;21(3):254-258. doi: 10.5114/wo.2017.70116. Epub 2017 Sep 29.

11.

Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.

Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, Stencel K, Ramlau-Piątek K, Segiet A, Skroński M, Grudny J, Chorostowska-Wynimko J.

Oncol Lett. 2017 Nov;14(5):5611-5618. doi: 10.3892/ol.2017.6907. Epub 2017 Sep 7.

12.

Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.

Roś-Mazurczyk M, Wojakowska A, Marczak Ł, Polański K, Pietrowska M, Polanska J, Dziadziuszko R, Jassem J, Rzyman W, Widlak P.

Acta Biochim Pol. 2017;64(3):513-518. doi: 10.18388/abp.2017_1517. Epub 2017 Aug 12.

13.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

14.

Radiation dose to the left anterior descending coronary artery during interstitial pulsed-dose-rate brachytherapy used as a boost in breast cancer patients undergoing organ-sparing treatment.

Sinacki M, Serkies K, Dziadziuszko R, Narkowicz M, Kamińska J, Lipniewicz J.

J Contemp Brachytherapy. 2017 Feb;9(1):7-13. doi: 10.5114/jcb.2017.66043. Epub 2017 Feb 15.

15.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.

Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.

16.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Med Sci Monit. 2017 Mar 9;23:1208-1216.

17.

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.

J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.

18.

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

Serkies K, Jaśkiewicz J, Dziadziuszko R, Jassem J.

J Contemp Brachytherapy. 2016 Dec;8(6):492-496. doi: 10.5114/jcb.2016.64512. Epub 2016 Dec 9.

19.

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.

Szutowicz-Zielińska E, Konopa K, Kowalczyk A, Suszko-Każarnowicz M, Duchnowska R, Szczęsna A, Ratajska M, Sowa A, Limon J, Biernat W, Burzykowski T, Jassem J, Dziadziuszko R.

Oncotarget. 2017 Mar 7;8(10):17270-17278. doi: 10.18632/oncotarget.13793.

20.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR.

J Thorac Oncol. 2017 Jan;12(1):110-120. doi: 10.1016/j.jtho.2016.09.002. Epub 2016 Sep 14.

21.

Whole Brain Radiotherapy for Patients with Non-Small Cell Lung Cancer with EGFR Mutations-Why and When?

Dziadziuszko R.

J Thorac Oncol. 2016 Oct;11(10):1604-5. doi: 10.1016/j.jtho.2016.08.121. No abstract available.

22.

Serum mass profile signature as a biomarker of early lung cancer.

Widlak P, Pietrowska M, Polanska J, Marczyk M, Ros-Mazurczyk M, Dziadziuszko R, Jassem J, Rzyman W.

Lung Cancer. 2016 Sep;99:46-52. doi: 10.1016/j.lungcan.2016.06.011. Epub 2016 Jun 16.

PMID:
27565913
23.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

24.

[Molecular diagnostics of lung cancer].

Ryska A, Dziadziuszko R, Olszewski W, Berzinec P, Öz B, Gottfried M, Cufer T, Samarzija M, Plank L, Ostoros G, Tímár J.

Magy Onkol. 2015 Sep;59(3):259-66. Epub 2015 Aug 18. Review. Hungarian.

25.

Early results of a trimodality treatment for superior sulcus tumors.

Łapiński M, Dziadziuszko R, Sawicka W, Rzyman W.

Kardiochir Torakochirurgia Pol. 2014 Sep;11(3):268-72. doi: 10.5114/kitp.2014.45675. Epub 2014 Sep 28.

26.

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.

Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, Bajcic P, Dusšk L, Zbozinkova Z, Pirker R; INSIGHT study team.

J Thorac Oncol. 2015 Sep;10(9):1370-1374. doi: 10.1097/JTO.0000000000000621.

27.

Stereotactic body radiotherapy for central lung tumours: Author reply.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U.

Br J Radiol. 2015 Sep;88(1053):20150532. doi: 10.1259/bjr.20150532. Epub 2015 Jul 7. No abstract available.

28.

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.

Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F.

J Thorac Oncol. 2015 Jul;10(7):1067-75. doi: 10.1097/JTO.0000000000000549.

29.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

30.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

31.

LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U.

Br J Radiol. 2015 Jul;88(1051):20150036. doi: 10.1259/bjr.20150036. Epub 2015 Apr 15.

32.

CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.

Jarząbek T, Rucińska M, Rogowski W, Lewandowska M, Tujakowski J, Habib M, Kowalczyk A, Byszek A, Dziadziuszko R, Nawrocki S.

Mol Diagn Ther. 2015 Apr;19(2):79-89. doi: 10.1007/s40291-015-0132-9.

33.

Activation of RAS family members confers resistance to ROS1 targeting drugs.

Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S.

Oncotarget. 2015 Mar 10;6(7):5182-94.

34.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.

J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.

PMID:
25667280
35.

Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.

Krawczyk P, Chorostowska-Wynimko J, Dziadziuszko R, Jassem J, Krzakowski M, Langfort R, Puacz E, Wasąg B, Wojas-Krawczyk K.

Pneumonol Alergol Pol. 2014;82(5):437-44. doi: 10.5603/PiAP.2014.0057.

36.

Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study.

Thunnissen E, Noguchi M, Aisner S, Beasley MB, Brambilla E, Chirieac LR, Chung JH, Dacic S, Geisinger KR, Hirsch FR, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Pelosi G, Petersen I, Roggli V, Travis WD, Wistuba I, Yatabe Y, Dziadziuszko R, Witte B, Tsao MS, Nicholson AG.

J Thorac Oncol. 2014 Sep;9(9):1354-62. doi: 10.1097/JTO.0000000000000264.

37.

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.

Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powrózek T, Lewandowska MA, Limon J, Wasąg B, Pankowski J, Kozielski J, Kalinka-Warzocha E, Szczęsna A, Wojas-Krawczyk K, Skroński M, Dziadziuszko R, Jaguś P, Antoszewska E, Szumiło J, Jarosz B, Woźniak A, Jóźwicki W, Dyszkiewicz W, Pasieka-Lis M, Kowalski DM, Krzakowski M, Jassem J, Milanowski J.

J Cancer Res Clin Oncol. 2015 Jan;141(1):61-8. doi: 10.1007/s00432-014-1789-x. Epub 2014 Aug 3.

38.

Of mice and men: olfactory neuroblastoma among animals and humans.

Lubojemska A, Borejko M, Czapiewski P, Dziadziuszko R, Biernat W.

Vet Comp Oncol. 2016 Sep;14(3):e70-82. doi: 10.1111/vco.12102. Epub 2014 Jul 12. Review.

PMID:
25041470
39.

Identification of serum proteome components associated with progression of non-small cell lung cancer.

Pietrowska M, Jelonek K, Michalak M, Roś M, Rodziewicz P, Chmielewska K, Polański K, Polańska J, Gdowicz-Kłosok A, Giglok M, Suwiński R, Tarnawski R, Dziadziuszko R, Rzyman W, Widłak P.

Acta Biochim Pol. 2014;61(2):325-31. Epub 2014 May 29.

40.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

41.

Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

Zimmermann S, Dziadziuszko R, Peters S.

Cancer Treat Rev. 2014 Jul;40(6):716-22. doi: 10.1016/j.ctrv.2014.03.005. Epub 2014 Apr 8. Review.

PMID:
24759599
42.

Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report.

Dziadziuszko K, Szurowska E, Pienkowska J, Jassem J, Dziadziuszko R.

J Thorac Oncol. 2014 May;9(5):e34-6. doi: 10.1097/JTO.0000000000000091. No abstract available.

43.

[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].

Jassem J, Biernat W, Bryl M, Chorostowska-Wynimko J, Dziadziuszko R, Krawczyk P, Kordek R, Kowalski DM, Krzakowski M, Olszewski W, Orłowski T, Ramlau R, Rzyman W.

Pneumonol Alergol Pol. 2014;82(2):133-49. doi: 10.5603/PiAP.2014.0019. Review. Polish.

44.

Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer.

Dziadziuszko R, Jassem J.

J Thorac Oncol. 2013 Dec;8(12):1465-6. doi: 10.1097/JTO.0000000000000054. No abstract available.

45.

Pulsed dose rate brachytherapy of lip cancer.

Serkies K, Ziemlewski A, Sawicki T, Kamińska J, Dziadziuszko R.

J Contemp Brachytherapy. 2013 Sep;5(3):144-7. doi: 10.5114/jcb.2013.37777. Epub 2013 Sep 20.

46.

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Jassem J, Dziadziuszko R.

Lancet Oncol. 2013 Sep;14(10):916-7. doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22. No abstract available.

PMID:
23883923
47.

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

Skrzypski M, Dziadziuszko R, Jassem E, Szymanowska-Narloch A, Gulida G, Rzepko R, Biernat W, Taron M, Jelitto-Górska M, Marjański T, Rzyman W, Rosell R, Jassem J.

Clin Lung Cancer. 2013 Nov;14(6):666-673.e2. doi: 10.1016/j.cllc.2013.04.010. Epub 2013 Jul 17.

PMID:
23870818
48.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

Dziadziuszko R, Jassem J.

Ann Oncol. 2012 Sep;23 Suppl 10:x193-6.

PMID:
22987961
49.

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.

Duchnowska R, Dziadziuszko R, Trojanowski T, Mandat T, Och W, Czartoryska-Arłukowicz B, Radecka B, Olszewski W, Szubstarski F, Kozłowski W, Jarosz B, Rogowski W, Kowalczyk A, Limon J, Biernat W, Jassem J; Polish Brain Metastasis Consortium.

Breast Cancer Res. 2012 Aug 16;14(4):R119. doi: 10.1186/bcr3244.

50.

A lack of correlation between mast cells, angiogenesis, and outcome in non-small cell lung cancer.

Niczyporuk M, Hermanowicz A, Matuszczak E, Dziadziuszko R, Knaś M, Zalewska A, Chyczewski L.

Exp Lung Res. 2012 Aug;38(6):281-5. doi: 10.3109/01902148.2012.686559. Epub 2012 May 30.

PMID:
22646306

Supplemental Content

Loading ...
Support Center